Literature DB >> 10515447

Improved artificial death switches based on caspases and FADD.

L Fan1, K W Freeman, T Khan, E Pham, D M Spencer.   

Abstract

A number of "suicide genes" have been developed as safety switches for gene therapy vectors or as potential inducible cytotoxic agents for hyperproliferative disorders, such as cancer or restenosis. However, most of these approaches have relied on foreign proteins, such as HSV thymidine kinase, that primarily target rapidly dividing cells. In contrast, novel artificial death switches based on chemical inducers of dimerization (CIDs) and endogenous proapoptotic molecules function efficiently in both dividing and nondividing cells. In this approach, lipid-permeable, nontoxic CIDs are used to conditionally cross-link target proteins that are fused to CID-binding domains (CBDs), thus activating signaling cascades leading to apoptosis. In previous reports, CID-regulated Fas and caspases 1, 3, 8, and 9 were described. Since the maximum efficacy of these artificial death switches requires low basal and high specific activity, we have optimized these death switches for three parameters: (1) extent of oligomerization, (2) spacing between CBDs and target proteins, and (3) intracellular localization. We describe improved conditional Fas and caspase 1, 3, 8, and 9 alleles that function at subnanomolar levels of the CID AP1903 to trigger apoptosis. Further, we demonstrate for the first time that oligomerization of the death effector domain of the Fas-associated protein, FADD, is sufficient to trigger apoptosis, suggesting that the primary function of FADD, like that of Apaf-1, is oligomerization of associated caspases. Finally, we demonstrate that nuclear-targeted caspases 1, 3, and 8 can trigger apoptosis efficiently, implying that the cleavage of nuclear targets is sufficient for apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10515447     DOI: 10.1089/10430349950016924

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  43 in total

1.  Activation of iCaspase-9 in neovessels inhibits oral tumor progression.

Authors:  M S Pinsky; W Song; Z Dong; K Warner; B Zeitlin; E Karl; D E Hall; J E Nör
Journal:  J Dent Res       Date:  2006-05       Impact factor: 6.116

2.  Redirecting tyrosine kinase signaling to an apoptotic caspase pathway through chimeric adaptor proteins.

Authors:  Perry L Howard; Marie C Chia; Suzanne Del Rizzo; Fei-Fei Liu; Tony Pawson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-17       Impact factor: 11.205

3.  An inducible caspase 9 safety switch for T-cell therapy.

Authors:  Karin C Straathof; Martin A Pulè; Patricia Yotnda; Gianpietro Dotti; Elio F Vanin; Malcolm K Brenner; Helen E Heslop; David M Spencer; Cliona M Rooney
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

4.  Double-inducible gene activation system for caspase 3 and 9 in epidermis.

Authors:  Viraj R Shah; Maranke I Koster; Dennis R Roop; David M Spencer; Lei Wei; Qi Li; Robert J Schwartz; Jiang Chang
Journal:  Genesis       Date:  2007-04       Impact factor: 2.487

5.  Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes.

Authors:  Yozo Nakazawa; Leslie E Huye; Gianpietro Dotti; Aaron E Foster; Juan F Vera; Pallavi R Manuri; Carl H June; Cliona M Rooney; Matthew H Wilson
Journal:  J Immunother       Date:  2009-10       Impact factor: 4.456

6.  Safeguarding nonhuman primate iPS cells with suicide genes.

Authors:  Bonan Zhong; Korashon L Watts; Jennifer L Gori; Martin E Wohlfahrt; Joerg Enssle; Jennifer E Adair; Hans-Peter Kiem
Journal:  Mol Ther       Date:  2011-05-17       Impact factor: 11.454

7.  Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.

Authors:  Iulia Diaconu; Brandon Ballard; Ming Zhang; Yuhui Chen; John West; Gianpietro Dotti; Barbara Savoldo
Journal:  Mol Ther       Date:  2017-02-08       Impact factor: 11.454

8.  Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.

Authors:  Xiaoou Zhou; Gianpietro Dotti; Robert A Krance; Caridad A Martinez; Swati Naik; Rammurti T Kamble; April G Durett; Olga Dakhova; Barbara Savoldo; Antonio Di Stasi; David M Spencer; Yu-Feng Lin; Hao Liu; Bambi J Grilley; Adrian P Gee; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner
Journal:  Blood       Date:  2015-05-14       Impact factor: 22.113

Review 9.  Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

Authors:  Thomas Shum; Robert L Kruse; Cliona M Rooney
Journal:  Expert Opin Biol Ther       Date:  2018-05-14       Impact factor: 4.388

10.  Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells.

Authors:  W Song; Z Dong; T Jin; M G Mantellini; G Núñez; J E Nör
Journal:  Cancer Gene Ther       Date:  2008-06-20       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.